Related Experiment Video

Updated: Aug 2, 2026

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System
11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth

A Miyajima1, T Asano, M Hayakawa

  • 1Department of Urology, National Defense Medical College, Saitama, Japan.

The Journal of Urology
|February 15, 2001
PubMed
Abstract

Insights

Captopril inhibits renal cancer cell growth by restoring transforming growth factor-beta type II receptor expression, increasing cell sensitivity to this growth-inhibitory cytokine.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Captopril is recognized for its potential to inhibit renal cancer growth.
  • The precise mechanism underlying captopril's anti-cancer effects, particularly its interaction with growth factors, remains largely undetermined.
  • Transforming growth factor-beta (TGF-β) is a key cytokine known to inhibit epithelial cell proliferation.

Purpose of the Study:

  • To elucidate the mechanism by which captopril inhibits the growth of the Renca mouse renal cancer cell line.
  • To investigate the role of transforming growth factor-beta (TGF-β) in captopril-mediated renal cancer cell growth inhibition.

Main Methods:

  • Cell viability was assessed using bromodeoxyuridine (BrdU) incorporation and tetrazolium bromide assays.
  • Transforming growth factor-beta (TGF-β) levels in conditioned medium were quantified via bioassay.
  • Messenger RNA (mRNA) expression of TGF-β and its type II receptor were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry.

Main Results:

  • Captopril treatment (0.01 to 1 mM) did not significantly alter TGF-β synthesis or its mRNA levels in Renca cells.
  • A concentration of 1 mM captopril markedly inhibited Renca cell proliferation.
  • RT-PCR and flow cytometry revealed that 1 mM captopril significantly upregulated the expression of the TGF-β type II receptor.

Conclusions:

  • Captopril treatment restores the expression of the transforming growth factor-beta (TGF-β) type II receptor in Renca cells.
  • This restoration enhances the sensitivity of Renca cells to TGF-β.
  • The findings suggest that captopril inhibits renal cancer cell growth by modulating TGF-β signaling pathways.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: